Biosimilar epoetins and other "follow-on" biologics: Update on the European experiences

Wolfgang Jelkmann*

*Corresponding author for this work
76 Citations (Scopus)


After the patents of biopharmaceuticals have expired, based on specific regulatory approval pathways copied products ("biosimilars" or "follow-on biologics") have been launched in the EU. This article summarizes experiences with hematopoietic medicines, namely the epoetins (two biosimilars traded under five different brand names) and the filgrastims (two biosimilars, six brand names). Physicians and pharmacists should be familiar with the legal and pharmacological specialities of biosimilars: The production process can differ from that of the original, clinical indications can be extrapolated, glycoproteins contain varying isoforms, the formulation may differ from the original, and biopharmaceuticals are potentially immunogenic. Only on proof of quality, efficacy and safety, biosimilars are a viable option because of their lower costs.

Original languageEnglish
JournalAmerican Journal of Hematology
Issue number10
Pages (from-to)771-780
Number of pages10
Publication statusPublished - 10.2010

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Biosimilar epoetins and other "follow-on" biologics: Update on the European experiences'. Together they form a unique fingerprint.

Cite this